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Translational relevance: 
Currently there are no effective targeted therapies for triple negative breast cancer (TNBC). 
We show that the Luminal Androgen Receptor subtype of TNBC is highly sensitive to 
CDK4/6 inhibition whilst basal-like TNBC tumours are resistant. Differential sensitivity of 
TNBC subtypes to CDK4/6 inhibition is shown to be a result of cells exiting mitosis into an 
active proliferating or a quiescent state. Basal-like TNBC have a high proportion of active 
proliferating cells, that are resistant to CDK4/6 inhibition, promoted by dysregulation of cyclin 
E1 expression. Our results identify novel therapeutic approaches for TNBC, and identify 
mechanisms of sensitivity to CDK4/6 inhibitors. 
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Abstract (251 words) 
Purpose: Triple negative breast cancer (TNBC) is a heterogeneous subgroup of breast 
cancer that is associated with poor prognosis. We evaluated the activity of CDK4/6 inhibitors 
across TNBC subtypes, and investigated the mechanisms of sensitivity. 
Experimental design: A panel of cell lines representative of TNBC were tested for CDK4/6 
sensitivity, in vitro and in vivo. A fluorescent CDK2 activity reporter was used for single cell 
analysis in conjunction with time-lapse imaging.  
Results: The luminal androgen receptor (LAR) subtype of TNBC was highly sensitive to 
CDK4/6 inhibition both in vitro [p<0.001 LAR vs. basal-like] and in vivo in MDA-MB-453 LAR 
cell line xenografts. Single cell analysis of CDK2 activity demonstrated difference in cell 
cycle dynamics between LAR and basal-like cells. Palbociclib-sensitive LAR cells exit 
mitosis with low levels of CDK2 activity, into a quiescent state that requires CDK4/6 activity 
for cell cycle re-entry. Palbociclib-resistant basal-like cells exit mitosis directly into a 
proliferative state, with high levels of CDK2 activity, bypassing the restriction point and the 
requirement for CDK4/6 activity. High CDK2 activity post-mitosis is driven by temporal 
deregulation of cyclin E1 expression. CDK4/6 inhibitors were synergistic with PI3 kinase 
inhibitors in PIK3CA mutant TNBC cell lines, extending CDK4/6 inhibitor sensitivity to 
additional TNBC subtypes. 
Conclusion: Cell cycle dynamics determines response to CDK4/6 inhibition in TNBC. 
CDK4/6 inhibitor, alone and in combination, are a novel therapeutic strategy for specific 
subgroups of TNBC. 
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Introduction: 
The CDK4/6 – RB1 axis controls transition through the restriction point in the G1 phase of 
the cell cycle, and cancers frequently subvert the regulation of this axis to promote 
proliferation[1, 2]. CDK4/6 inhibition is a proven therapeutic strategy for oestrogen receptor 
positive (ER+ve) breast cancers [3, 4], with selective CDK4/6 inhibitors (palbociclib and 
ribociclib) demonstrating substantial improvements in progression free survival 
(PALOMA1[3], PALOMA2[5], PALOMA3[4] and MONALEESA-2[6]) in phase two and three 
clinical trials.  
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated 
with poor prognosis. Although TNBC may be sensitive to chemotherapy there is a 
substantial need to identify novel targeted therapeutic strategies. TNBC are a 
heterogeneous group of tumours with gene expression profiling identifying distinct 
subgroups [7, 8], including luminal androgen receptor (LAR), mesenchymal stem like (MSL), 
mesenchymal (MES), and basal-like [7]. The majority of TNBC fall within the dominant basal-
like and MES subgroups. TNBC are highly proliferative tumours enriched for high expression 
of cell cycle genes [7], yet as a heterogeneous group are considered to be largely resistant 
to CDK4/6 inhibition [9], as are many other tumour types.  
The determinants of sensitivity to CDK4/6 inhibition are poorly understood. Loss of 
retinoblastoma protein (RB1) causes resistance to CDK4/6 inhibition [10], however for the 
majority of cancers, the factors that determine sensitivity or resistance to CDK4/6 inhibitors 
are unclear. Recent studies of cell cycle dynamics have redefined our understanding of the 
mitosis-S phase transition in asynchronously dividing cells [11-13], with cells at mitotic exit 
entering either a quiescent or an active-proliferative state [12, 13]. Here we show that cell 
cycle exit into a quiescent or proliferative state is a major factor determining sensitivity to 
CDK4/6 inhibitors. We identify subgroups of TNBC that are highly sensitive to CDK4/6 
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inhibition, and using a CDK2 activity live-cell reporter [12] we show that CDK2 activity after 
mitotic exit dictates sensitivity to CDK4/6 inhibition.  
 
Methods 
Cell lines  
Cell lines were obtained from ATCC or Asterand and maintained according to the 
manufacturer's instructions. Cell lines were banked in multiple aliquots on receipt, identity 
confirmed by STR profiling with the PowerPlex 1.2 System (Promega) and tested for 
mycoplasma every two weeks. 
Palbociclib-resistant MFM223pR cells were generated by chronic exposure to increasing 
concentrations of palbociclib (100, 250, 500, 1000nmol) over 4 months. Drug treatments 
were replaced every 3-4 days with fresh media. 
 
Antibodies, reagents and constructs 
Phospho-RB1 S807/811 (8516), RB1 (9313), Cyclin E1 (HE12; 4129), Cyclin E2 (4132), 
CDK2 (2546), phospho-CDK2 T160 (2561); CDK4 (12790), Androgen Receptor (3202) were 
all Cell Signalling Technology, Danvers, MA; p16 F-12 (SC-1661, Santa Cruz), -actin 
(A5441, Sigma); Cyclin E1 (ab33911) and c-myc (ab32072) were Abcam. Western blot 
analysis was performed using pre-cast 4-12% SDS gels, as described previously [14]. 
Densitometry analysis was performed on western blot films using ImageJ software (National 
Institute of Health, USA), and expressed relative to their corresponding loading control. 
 
Palbociclib (PD-0332991; SelleckChem) was used at 500nmol, pictilisib (GDC-0941; 
SelleckChem) at 200nmol, and taselisib (GDC-0032; Genentech) at 100nmol, unless 
otherwise stated. Palbociclib 500nmol was used for the majority of experiments as 
previously [10]. No increase in effect on clonogenic growth was observed with doses above 
500nmol (Fig. 1A). 
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siRNAs were from Thermofisher Scientific: siCCNE1 (#4390824, #4390824, #1299001), 
siCON1 (#4390843), siCON2 (#4390846) and siUBB (# 4390824). 
The CDK2 activity live-cell sensor (CDK2L-GFP) was generated by cloning the C-terminal 
PSLD region of Human DNA Helicase B (DHB; 957-1087 amino acids) into pIRES-GFP 
puromicin as described previously[11]. PCNA was tagged at the N terminus with the 
modified LSS2-mKate fluoro-phore to generate LSS2-mKate-PCNA[15].  
 
Cell Transfections 
For CDK2 activity sensor experiments, cells were transfected with CDK2L-GFP using 
Lipofectamine® 2000 according to the manufacturer’s instructions, 48-72 hours prior 
imaging. For siRNA knockdown experiments, SUM149 cells were transfected with CDK2L-
GFP on day one, then GFP-positive cells (3000 cells/well) were FACS-sorted into 384-well 
plate on day 3, and next siRNA transfection using siCON1 and siCCNE1 was performed with 
Lipofectamine® RNAiMAX on day 6, followed by time-lapse imaging on days 9-11. As 
previously demonstrated, the CDK2L-GFP sensor is not phosphorylated by CDK4/6 [11], nor 
by CDK1 [12]. 
 
Time-lapse microscopy 
CDK2L-GFP positive cells were FACS sorted into 384 well plates, with 1000 to 3000 cells 
seeded per well, 24 hours prior time-lapse imaging. Unless specified, drugs or vehicle were 
added immediately prior time-lapse experiments. Images were taken on a High-content 
Opera Spinning Disk confocal microscope (PerkinElmer) with 40X water objective, every 10 
minutes, in a NA 0.9 humidified environmental chamber at 370C and 5% CO2. 
 
To assess the impact of palbociclib on S phase entry in SUM149 cells (Fig. 3A), palbociclib 
or vehicle (DMSO) was added 8 hours after initiation of CDK2L-GFP time-lapse imaging, 
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with continued imaging for a further 48 hours. Analysis was restricted to cells that underwent 
mitosis 1-3 hours prior to adding palbociclib or vehicle (DMSO).  
 
To study stability of CDK2 activity in individual cell clones (Fig. 5D and Supplementary Fig. 
4A), a single cell was FACS-sorted into each well of the 96 well plate, with single cell sorting 
confirmed by bright field microscopy. Plates were incubated for 4 weeks to generate clonal 
populations. Individual wells were transfected with CDK2L-GFP, and 48 hours later imaged 
using time-lapse microscopy. All examined clonal populations were STR typed. 
 
Image analysis 
Time frames of cells transfected with CDK2L-GFP or LSS2-mKate-PCNA were captured at 
10 minutes intervals over a 48-72 hours period. Dynamic changes of CDK2L-GFP or LSS2-
mKate-PCNA were manually tracked in individual cells using Volocity (PerkinElmer). To 
quantify CDK2 activity, both nuclear and peri-nuclear cytoplasmic CDK2L-GFP intensity 
were measured simultaneously. CDK2 activity for each time point was calculated as a ratio 
of mean GFP fluorescent intensity in the cytoplasm divided by the mean GFP fluorescent 
intensity in the nucleus. For representation, asynchronous single cell CDK2 activity traces 
were aligned in silico to time of cytokinesis as T0 (time-point = 0). The CDK2 activity traces 
were smoothed with a window of 4 data points minimize background noise.  
 
Cell cycle length (hours) was calculated as the time from first cytokinesis to the second 
cytokinesis. Unless stated otherwise, post-mitotic CDK2 activity was assessed as the CDK2 
activity at 2 hours post-cytokinesis, as the first time-point across imaged cell lines that 
allowed reliable quantification of CDK2 activity after reformation of the nuclear membrane 
and cell flattening [11]. Cells with CDK2 activity <0.6 at 2 hours post cytokinesis were 
defined as CDK2low, and cells with CDK2 activity >0.6 at 2 hours points post cytokinesis 
were defined as CDK2high, as previously described [12]. In PCNA tracking experiments S-
phase entry was defined a sharp increase in PCNA intensity with the appearance of nucleoli, 
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as previously described [11]. Accumulation of CDK2 activity to a ratio of 1 was used as 
surrogate for cell cycle entry, as previously demonstrated [12]. 
 
Immunofluorescence 
Immediately after time lapse, cells were fixed in 4% paraformaldehyde, washed three times 
in PBS, permeabilized with 0.2% Triton X-100, and stained at room temperature using 
mouse and rabbit primary antibodies, detected with corresponding fluorescent secondary 
antibodies: anti-mouse Alexa Fluor-555 and anti-rabbit Alexa Fluor-647. Nuclear pixels were 
measured as an output of intensity for each cell, using Columbus™ image data storage and 
analysis system. 
 
Nuclear cyclin E1 protein levels in individual LAR MDAMB453 cells and basal-like SUM149 
cells 1-2 hours after mitosis (Fig. 4D), was determined by time-lapse imaging of CDK2L-GFP 
positive cells (24 hours), followed by immunofluorescence for cyclin E1. Nuclear cyclin E1 
protein levels were quantified by measuring the intensity of the immunofluorescence signal 
with Columbus™ imaging software, specifically in cells that had undergone mitoses 1-2 
hours prior to fixation. 
 
Immunohistochemistry 
For immunohistochemical analysis of MDAMB453 xenografts, tumours were extracted 4 
hours post-dose and formalin fixed for immunohistochemistry (IHC).  Each sampling time 
point includes 4 animals /treatment group.  IHC was performed on 4um thick formalin-fixed, 
paraffin-embedded tissue sections mounted on glass slides.   For cleaved caspase 3 (Cell 
Signaling Technologies, Danvers, MA), staining was performed on a DAKO autostainer. 
Sections were treated with DAKO Target Retrieval (Dako; Carpinteria, CA), incubated with 
primary antibody at 0.12ug/ml overnight at 4°C followed by biotinylated goat anti-rabbit IgG 
(Vectorlabs, Burlingame, CA) and detected with Vectastain ABC-HRP (Vectorlabs, 
Burlingame, CA). For phospho-S6, IHC was performed on the Ventana Discovery XT 
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Autostainer platform (Ventana Medical Systems Inc, Tucson, AZ).  The slides were pre-
treated with CC1, standard time, followed by anti-phospho-S6 (Cell Signaling Technologies, 
Danvers, MA), incubated at 0.26ug/ml for 32 minutes at 37°C.   The antibody was detected 
with anti-rabbit-UltraMap (Ventana Medical Systems Inc, Tucson, AZ).  Staining was 
visualized with DAB. Sections were counter stained with hematoxylin, dehydrated, cleared 
and cover-slipped for viewing.   
 
Assessment of viability and proliferation 
All clonogenic assays were conducted in triplicates of 6-well plates, with 1000 to 5000 cells 
seeded per well 24 hour prior to exposure to the indicated drug concentrations, or vehicle. 
Wells were treated continuously for at least 2 weeks replacing media/drug every 3-4 days. 
Plates were fixed with tricyclic acid (10%), stained with sulforhodamine B (SRB) and 
absorbance measured. Absorbance for drug treated wells was expressed relative to the 
control wells, with subtraction of the background SRB absorbance from an empty well. The 
mean of at least three replicate wells was calculated for each dose/combination. 
Synergy was assessed using SRB absorbance from long-term clonogenic assays. Wells 
were treated every 3-4 days with palbociclib: 0, 100, 250, 500 or 750nmol, and/or pictilisib: 0, 
100, 200, 400, 500 or 1000nmol. For AZD2014, wells were treated every 3-4 days with 
palbociclib: 0, 100, 250, 500 or 750nmol, and/or AZD2014: 0, 50, 100, 200, 400 and 
750nmol. Assessment of compound synergy was conducted using Bliss independence 
score. A Bliss additivity score of <-1.0 was consider synergistic for that combination of drug 
concentrations. A cell line was considered to show drug synergy if at least 3 different 
combinations of drug concentrations were synergistic.   
S phase fraction was assayed after 24 or 72 hours exposure to compounds, with the addition 
of for 2 hours prior to fixing. BrdU incorporation was assessed with Cell 
Proliferation chemiluminescent ELISA-BrdU assay (Roche 11 669 915 001) according to 
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manufacturer’s instructions and adjusted for viable cells in parallel wells assessed with 
CellTiter-Glo®.  
 
Tumour xenografts  
In vivo efficacy and pharmacodynamic studies were approved by Genentech’s Institutional 
Animal Care and Use Committee (IACUC) and adhered to the ILAR Guide for the Care and 
Use of Laboratory Animals.  Naïve female C.B-17 SCID mice (Charles River Laboratories, 
San Diego, CA) were inoculated into the right 2/3 mammary fat pad with 20 million 
MDAMB453 cells suspended in a 1:1 ratio of HBSS and phenol red-free matrigel (BD 
Biosciences, San Jose, CA).  Once tumours reached a mean volume of about 300 mm3, 
mice with similarly sized tumours were distributed into treatment cohorts (n=10/group).  Mice 
were dosed daily and orally, with vehicle [0.5% methylcellulose/0.2% tween-80 (MCT)], 5 
mg/kg taselisib (GDC-0032), 50 mg/kg palbociclib or the combination of taselisib and 
palbociclib for 21 consecutive days. Length (l) and width (w) of each tumour were measured 
using digital calipers (Fred V. Fowler Company, Inc., Newton, MA) and tumour volumes were 
calculated based on the following formula:  tumour volume = l x w2 x 0.5.   
 
Analysis of publically - available data sets  
The METABRIC dataset (n=1991) was obtained by application to the European Genome-
phenome archive [16]. 320 putative TNBC samples were normalised using the beadarray 
package [17] and classified using TNBC type [18]. 5 samples were then removed as putative 
ER positive samples leaving 315 for analysis.  Segmented (CBS) copy number logR ratios 
were downloaded and used for copy number analysis, with gain/loss thresholds as 
previously defined [16]. Heat maps representing key cell cycle genes were generated in R. 
For 102 TCGA samples representing TNBC, level 3 RNA-seq data (raw gene counts) was 
downloaded from the TCGA web site for these samples. The gene counts were normalised 
using edgeR packages. Copy number, mutation and RPPA data was extracted from 
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cBioPortal using the CGDS-R (http://www.cbioportal.org/cgds_r.jsp). Additional data was 
downloaded from the Cancer Proteome Atlas project [17].  
 
Statistical analysisFor in vitro studies, all statistical tests were performed with GraphPad 
Prism version 6.0. P-values were two-tailed and considered significant if P < 0.05. Error bars 
represent Standard deviation or SEM of three experiments. Assessment of compound 
synergy was conducted using Bliss independence score.  
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Results 
Luminal Androgen Receptor (LAR) subtype of triple negative breast cancer is 
sensitive to CDK4/6 inhibition 
We investigated whether the different molecular subgroups of TNBC were sensitive to 
CDK4/6 inhibition. Clonogenic assays were performed on a panel of 12 RB1 wild-type TNBC 
cell lines and one RB1 mutant cell line (BT549), with the CDK4/6 inhibitor palbociclib (Fig. 
1A and Fig. 1B). Cell lines from the dominant basal-like and mesenchymal (MES) subgroups 
of TNBC were resistant to palbociclib, whereas the LAR TNBC cell lines were highly 
sensitive to palbociclib (p<0.0001 basal-like vs. LAR), and ribociclib (Fig. 1C), with sensitivity 
similar to the oestrogen positive cell line MCF7 (Fig. 1B). In BrdU proliferation assays, 
palbociclib had a substantially greater effect on S phase entry in LAR compared to basal-like 
cell lines (Fig. 1D).  The sensitivity of LAR tumours to palbociclib was investigated in vivo in 
MDAMB453 xenografts. Tumour reductions were observed after the initial nine days of 
consecutive dosing (palbociclib oral 50mg/kg), with reduction in tumour size observed in 7 
out of 10 mice in the palbociclib treatment arm (Fig 1E).  
 
Palbociclib sensitive cell lines have low post-mitotic CDK2 activity 
We hypothesized that sensitivity to CDK4/6 inhibition would be determined by the level of 
CDK2 activity post-mitosis [12, 13]. To investigate this, we used a live cell fluorescent sensor 
to measure CDK2 activity (CDK2L) in five RB1 wild type TNBC models (Fig. 2A).  The 
CDK2L sensor specifically reports CDK2 activity, and is not phosphorylated by CDK4/6 and 
nor CDK1 (Methods).  
We measured CDK2 activity in individual cells as they transitioned through mitosis and into 
the next cell cycle. Individual cells in the LAR palbociclib-sensitive cell lines MFM223 and 
MDAMB435, exited mitosis with low levels of CDK2 activity, which continued to fall during 
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the first two hours post-mitosis (Fig. 2B and Supplementary Fig. 1A). The dynamics of CDK2 
activity after mitosis in the LAR cells were similar to CDK2 activity levels seen in the ER +ve 
MCF7 cell line (Supplementary Fig. 1B). In contrast, the palbociclib-resistant basal-like cell 
lines SUM149 and HCC1143 (Fig. 2C and Supplementary Fig. 1C), and the MES cell line 
CAL51 (Supplementary Fig. 1D), were predominately composed of cells that exited mitosis 
and started the next cell cycle with high levels of CDK2 activity, that rapidly accumulated 
higher levels of CDK2 activity. 
To compare CDK2 activity between cell lines, CDK2 activity levels were quantified 2 hours 
post-cytokinesis, the earliest time-point that allowed accurate quantification after nuclear 
envelope reformation. Basal-like TNBC cell lines had significantly higher CDK2 activity 
compared to the LAR cell lines (p<0.0001; Fig. 2D). Cells which exited mitosis with CDK2 
activity <0.6 at 2 hours post cytokinesis were defined as CDK2low, and cells with CDK2 
activity >0.6 at 2 hours post cytokinesis were defined as CDK2high [12]. Whereas LAR cells 
exited mitosis with a relatively homogeneous CDK2low phenotype, basal-like cells existed 
mitosis with heterogeneous CDK2 activity, with a large proportion of CDK2high cells (Fig. 2D). 
In basal-like and MES cell lines, CDK2high cells had substantially shorter cell cycles 
compared to CDK2low cells (p<0.0001; Fig. 2E and Supplementary Table 1). These results 
suggested that TNBC cell lines resistant to CDK4/6 inhibition were predominantly composed 
of actively proliferating CDK2high cells, whereas TNBC cell lines sensitive to CDK4/6 
inhibition were predominantly composed of more quiescent CDK2low cells. 
 
The proliferative CDK2high subpopulation drives resistance to CDK4/6 inhibition at the 
single cell level 
We hypothesised that the CDK2high subpopulation would be resistant to CDK4/6 inhibitors. 
The TNBC basal-like SUM149 model had a heterogeneous mix of CDK2 mitotic exit 
phenotypes with predominately CDK2high cells and a smaller fraction of CDK2low cells, and 
thus represented a good model to test this hypothesis. To assess the effect of palbociclib on 
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the two populations, SUM149 cells expressing CDKL2 were imaged for 8 hours prior to the 
addition of palbociclib or vehicle, and only cells that completed cytokinesis 1-3 hours prior to 
palbociclib addition were tracked. CDK2 activity was then assessed in individual cells for a 
further 48 hours post-treatment (methods). We observed that SUM149 cells that exited 
mitosis with a CDK2low phenotype were blocked from entering the cell cycle by palbociclib 
over the 48 hours duration of time lapse imaging (Fig. 3A), whereas cells that exited mitosis 
in a CDK2high state successfully entered the cell cycle despite palbociclib treatment and 
subsequently underwent a second mitosis (Fig. 3A and Fig. 3B). Therefore, although the 
SUM149 cell line was intrinsically resistance to palbociclib in long-term clonogenic assays, 
the sub-fraction of CDK2low cells were sensitive to palbociclib. Palbociclib did prolong cell 
cycle length in CDK2high cells (mean cell cycle length 20 hours vehicle versus 38 hours 
palbociclib, Fig. 3A) suggesting that CDK4/6 did facilitate, but was not essential for S-phase 
entry in CDK2high cells. After 14 days chronic treatment of SUM149 cells with palbociclib the 
length of the cell cycle returned towards pre-treatment levels, suggesting adaption to 
CDK4/6 inhibition (Supplementary Fig. 2A and 2B). Collectively this data demonstrates that 
post-mitotic CDK2 activity dictates sensitivity to CDK4/6 inhibition. CDK2high cells have 
sufficient CDK2 activity to bypass the restriction point, the point where CDK4/6 activity is 
necessary for cell cycle re-entry, resulting in CDK4/6 inhibitor resistance. 
We next established whether CDK2 activity at mitotic exit changed after acquired resistance 
to CDK4/6 inhibitors in LAR cell lines. We generated palbociclib-resistant cells from the 
MFM223 cell line (MFM223pR) via four months of chronic palbociclib exposure. In 
clonogenic assays, the MFM223pR were resistant to palbociclib, with a greater proportion of 
cells in S-phase during palbociclib treatment compared to the parental palbociclib sensitive 
cell line MFM223 (Fig. 3C). The MFM223pR model acquired higher protein levels of cyclin 
E1 and of the activating CDK2 T160 phosphorylation (Fig. 3D). In MFM223pR cells a new 
CDK2high proliferative subpopulation emerged (Fig. 3E), suggesting that the mechanism of 
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acquired resistance to palbociclib was due to a higher proportion of cells adopting the 
CDK2high phenotype.  
 
Temporal dysregulation of Cyclin E1 expression in TNBC cells drives higher CDK2 
activity post mitosis  
To explore the molecular determinants of CDK2high cells, we profiled our panel of TNBC cell 
lines. The LAR cell lines had both high expression of the androgen receptor (AR) (p=0.01) 
and absent/low expression of cyclin E1 (p=0.02) (Fig. 4A). We profiled TNBC tumours using 
publically available datasets. In both the METABRIC [16] and TCGA [19] datasets TNBC 
LAR tumours had significantly lower transcriptomic expression levels of CCNE1 (p<0.0001) 
and CDK2 (p<0.0001), with higher CDKN1A (p21) levels, as compared to basal-like TNBC 
(p=0.06) (Fig. 4B, Supplementary Figures 3A and 3B). Basal-like TNBC tumours had more 
frequently increased CCNE1 gene copy number than LAR tumours (p=0.008 Fisher’s exact 
test, Fig. 4B). There was a high correlation between cyclin E1 mRNA with protein levels 
(r=0.89; Supplementary Fig. 3C and 3D). 
 
Cyclin E1 is tightly regulated nuclear protein, periodically expressed during the cell cycle, 
with highest levels occurring during late G1 and early S-phase in non-cancer models [20]. 
We investigated the temporal regulation of cyclin E1 in palbociclib sensitive and resistant cell 
lines, in order to assess whether deregulation of cyclin E1 expression in early G1 promoted 
the CDK2high population. To test this we assessed the expression of nuclear cyclin E1 protein 
in individual cells 1-2 hours post-mitosis by dual immunofluorescence with CDK2L sensor 
(Methods). Basal-like SUM149 cells had aberrant high cyclin E1 expression post-mitosis 
(Fig. 4C-4D and Supplementary Fig. 3E) compared to LAR MDAMB453 cells that had 
uniform low cyclin E1 expression. This was substantially earlier than the time point where 
SUM149 cells typically entered S-phase, confirmed using a PCNA sensor (Supplementary 
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Fig. 3F). CDK2high SUM149 cells had higher cyclin E1 protein expression than CDK2low 
SUM149 cells (Fig. 4E). Silencing of cyclin E1 in SUM149 cells resulted in the loss of the 
CDK2high population post-mitosis, inducing a CDK2low phenotype (Fig. 4F and Supplementary 
Fig. 3G). Furthermore, silencing of cyclin E1 sensitised CAL51 (Fig. 4G and Supplementary 
Fig. 3H), SUM149 (Supplementary Fig. 3I) and MFM223pR to palbociclib, with minimal 
effects upon parental MFM223 cells that had low cyclin E1 expression (Fig. 4H). Cyclin E1 
silencing, without CDK4/6 inhibition, did not substantially reduce BrdU incorporation, likely 
due to redundancy between different CDKs and cyclins. Our data suggested that aberrant 
cyclin E1 expression immediately post-mitosis, promoted the CDK2high phenotype and 
resistance to CDK4/6 inhibition.  
 
The CDK2high phenotype is determined pre-mitosis  
We next addressed whether post-mitotic activity was determined pre-mitosis, as has been 
shown in non-cancer models [12]. SUM149 and CAL51 sister cell pairs, generated from the 
same mitosis, shared similar post-mitotic CDK2 activity (Fig. 5A and Fig. 5B) suggesting that 
the level of CDK2 activity post-mitosis was determined prior to cytokinesis. SUM149 cells 
with higher pre-mitotic CDK2 activity (2 hours prior to mitosis), generated daughter cells that 
entered S-phase despite CDK4/6 inhibition (Fig. 5C), whereas cells with lower pre-mitotic 
CDK2 activity were arrested by CDK4/6 inhibition (p=0.016).  
Having demonstrated that post-mitotic CDK2 activity was determined pre-cytokinesis, we 
investigated whether this was due to the existence of fixed sub-population of CDK2high cells, 
or whether CDK2high and CDK2low populations inter-converted. To test the long-term stability 
of the CDK2low and CDK2high subpopulations, we FACS sorted a single SUM149 cell (Fig. 
5D) and CAL51 cell (Supplementary Fig. 4A) into 96 well plates, confirmed single-cell 
seeding by microscopy, and assessed CDK2 activity in the resulting single cell clones after 
four weeks of multiplication. In general, clonal populations recapitulated variability in 
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CDK2high and CDK2low populations despite arising from a single cell (Fig. 5D and 
Supplementary Fig. 4).  The fraction of CDK2high cells was the most prevalent phenotype (50 
cells measured/well) across three of the four wells imaged in SUM149.  In contrast we 
identified a clonal SUM149 population that was robustly CDK2low (well E3) at a single time 
point, 2 hours post-cytokinesis, although it was not addressed whether greater heterogeneity 
in CDK2 activity could develop over time. Overall these results suggest that post-mitotic 
CDK2high activity is determined pre-mitosis, but these CDK2high and CDK2low subpopulations 
are not distinct fixed populations, with cells interconverting between phenotypes over many 
generations. 
The SUM149 cells have a BRCA1 mutation [21], which may have elevated levels of DNA 
damage. We hypothesized that the E3 clone, which maintained a large population of 
CDK2low cells, may have increased DNA damage. Immunofluorescence staining revealed 
that the SUM149 E3 clonal cell population had a higher percentage of gamma H2AX-, 
53BP1- and p21-positive cells, as compared to the F7 clonal population (Fig. 5E and Fig. 
5F). Parental SUM149 cells that exited mitosis with CDK2low phenotype were p21 positive by 
immunofluorescence (Fig. 5G), as previously observed in non-cancer models [12]. These 
results suggest that DNA damage and p21 expression may in part determine CDK2 activity 
state at mitotic exit [22]. 
 
Inhibition of PI3 kinase synergizing with CDK4/6 inhibitors in PIK3CA mutant TNBC 
The non-basal, LAR and MSL subtypes of TNBC are substantially enriched with activating 
mutations in the PI3 kinase catalytic subunit PIK3CA gene [23], and therefore we 
investigated the therapeutic potential of PI3 kinase pathway inhibitors in TNBC. A synergistic 
interaction (Bliss additivity score < -1.0) was observed between the pan class I PI3 kinase 
inhibitor pictilisib (GDC0941) and palbociclib in PIK3CA mutant TNBC cell lines (Fig. 6A), as 
we recently reported in ER+ve cell lines [10]. Combination synergy was not observed in 
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PIK3CA wild-type cell lines nor the RB1 mutant cell line BT549. Synergy was also observed 
with mTOR inhibitor AZD2014 - palbociclib combinations in PIK3CA mutant and some 
PIK3CA wild-type TNBC cell lines (Supplementary Fig. 5A). We further validated the efficacy 
of the drug combination with theα-selective PI3 kinase inhibitor taselisib (GDC0032), which 
substantially sensitised the MSL cell line SUM159 to palbociclib in clonogenic assays (Fig. 
6B) and BrdU proliferation assays (Supplementary Fig. 5B). These data suggested that 
combinations of PI3 kinase pathway inhibitors and CDK4/6 inhibitors could extend the utility 
of CDK4/6 inhibitors outside LAR subtype cancers. 
The combination of palbociclib and taselisib demonstrated greater efficacy than either 
compound alone in xenografts from the PIK3CA mutant LAR MDAMB453 cell line 
(palbociclib vs. combination p=0.02; taselisib vs. combination p=0.01, Fig. 6C). 
Pharmacodynamic studies at 1 hour and 4 hours time-points in the mouse tumours from 
MDAMB453 xenografts treated with individual drugs or the combination, demonstrated 
significant reduction in phosphorylated RB1 compared to vehicle (Fig 6D; vehicle versus. 
taselisib 1 hour p= 0.0004, 4 hours p<0.0001; vehicle vs. palbociclib 1 hour p< 0.0001, 4 
hours p< 0.0001; vehicle vs. combination 1 hour p< 0.0001, 4 hours p< 0.0001).  The 
combination induced greater levels of apoptosis than either drug alone (Supplementary Fig. 
5C).  
Finally, we examined whether PI3 kinase inhibition with taselisib affected post-mitotic CDK2 
levels, using the PIK3CA mutant MES CAL51 cell line. Taselisib decreased post-mitotic 
CDK2 activity with a greater proportion of cell that exit mitosis CDK2low (Fig. 6E). Pre-mitotic 
CDK2 levels influenced entry into the cell cycle post-mitosis (Supplementary Fig. 5D).  
These data suggested that the PI3 kinase inhibition sensitised to CDK4/6 inhibition, in part 
as PI3 kinase inhibition suppressed post mitotic CDK2 activity, inducing a CDK2low quiescent 
state where CDK4/6 activity was required to initiate the cell cycle.   
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We have shown that the luminal androgen receptor (LAR) subgroup of triple negative breast 
cancers (TNBC) is highly sensitive to CDK4/6 inhibition in vitro and in vivo (Fig. 1). 
Sensitivity to CDK4/6 inhibition is dictated at the single cell level, with resistance to CDK4/6 
inhibitors arising from cancer cells that exit mitosis directly into a CDK2high proliferative state, 
from which CDK4/6 is not necessary for cell cycle re-entry (Fig. 2C and Fig.3A). 
Our results further extend prior work in non-cancer models that demonstrate a biphasic exit 
of cells into proliferative and quiescent states after mitosis [12, 13]. Cells that exit mitosis 
with a CDK2low phenotype enter into a quiescent state, requiring CDK4/6 activity to initiate re-
entry into the cell cycle (Fig. 6F), and are hence sensitivity to CDK4/6 inhibition.  In contrast, 
cells that exit mitosis with a CDK2high phenotype enter into a proliferative state, bypassing the 
restriction point (Fig. 6G), with short doubling times. Tumours with a high proportion of 
CDK2high cells are resistant to CDK4/6 inhibition. Palbociclib-sensitive LAR cancer cells 
typically exit into a quiescent CDK2low state post-mitosis, from which CDK4/6 is required to 
phosphorylate RB1 and pass the restriction point [2, 24-27]. In contrast, basal-like TNBC 
cells frequently enter a proliferative CDK2high state and are thus resistant to palbociclib 
treatment. This provides a mechanistic explanation for why basal-like, and potentially many 
other tumour types are resistant to CDK4/6 inhibition despite being RB1 wild type. CDK4/6 
and PI3 kinase inhibitor combinations have substantial activity in PIK3CA mutant non-basal 
TNBC, of both LAR and mesenchymal-stem (MSL) subgroups (Fig. 6A), with such 
combinations having the potential to further expand the TNBC subgroups that could benefit 
from CDK4/6 inhibition 
Cyclin E1 binds to and activates CDK2 [28, 29] and prior work has demonstrated that cyclin 
E1 expression mediates resistance to CDK4/6 inhibition [10, 30].  The classical view is that 
CDK2 and cyclin E are downstream of CDK4/6 activity [24]. Here we show that in 
palbociclib-resistant TNBC, cyclin E1 expression is dysregulated and expressed immediately 
Asghar et al. 
Clinical Cancer Research 
Page 20 of 35 
 
post-mitosis (Fig. 4D). Dysregulated cyclin E1 promotes the CDK2high phenotype with CDK2-
CyclinE complex active immediately post-mitosis resulting in short G1 phase (Fig. 6G). 
SUM149 harbour an inactivating FBXW7 mutation that disrupts the SCF complex and likely 
contributes to dysregulated cyclin E1 expression (Supplementary table 2). In other contexts, 
increased CCNE1 gene copy number probably contributes to dysregulation of cyclin E1 
expression post-mitosis [10]. These observations suggest that measurement of cyclin E1 
expression either at the RNA or protein level has the potential to be utilised as a predictive 
biomarker of resistance to CDK4/6 inhibition in breast cancer. 
Daughter cells share the same CDK2 activity state, suggesting that post-mitotic CDK2 
activity is determined pre-mitosis (Fig. 5A). However, this is not the result of CDK2high and 
CDK2low cells, as colonies derived from individual cells largely recapitulate the same 
variability in CDK2 activity as the parental cell line (Fig. 5D). We provide some data to 
suggest that DNA damage, and the resulting induction of p21 expression, may also regulate 
CDK2 activity state post-mitosis (Fig. 5G). However, more research is required to further 
assess the potential role of DNA damaging signalling in this context.  
Our results illustrate how single cell analysis can identify mechanisms of resistance to 
targeted therapies. Phenotypic heterogeneity between single cells may drive drug 
resistance, and this may be more clearly elucidated at the single cell level than through 
assessment of bulk cell populations. Through single cell approaches, we identify CDK2 
activity post-mitosis as a key determinant of sensitivity to CDK4/6 inhibition, and highlight 
potential therapeutic strategies for triple negative breast cancer. An on going therapeutic trial 
is assessing the effectiveness of CDK4/6 inhibition in combination with PI3 kinase inhibition, 
in patients with PIK3CA-mutant TNBC (NCT02389842).  
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Figure 1. Luminal androgen receptor subgroup (LAR) of TNBC is sensitive to CDK4/6 
inhibition 
A. Clonogenic assays of triple negative breast cancer (TNBC) cell lines grown continuously 
in increasing concentrations of palbociclib, divided by gene expression subtypes: 
LAR=luminal androgen receptor, MSL=mesenchymal stem like, MES=mesenchymal and 
basal-like. All cell lines are RB1 wild-type except RB1 mutant BT549. 
B. Sensitivity to 500nmol palbociclib across 13 TNBC cell lines in clonogenic assays from 
part A. LAR subtype is highly sensitive to CDK4/6 inhibition [p<0.0001 Student’s T test LAR 
vs. basal-like]. ER+ve MCF7 cells are shown as positive control of sensitivity to palbociclib. 
C. Clonogenic assays of 5 TNBC cell lines treated with the CDK4/6 inhibitor ribociclib. 
D. Relative BrdU incorporation after 72 hours with or without 500nmol palbociclib for LAR 
cell lines (MFM223, MDAMB453 and SUM185), and basal-like cell lines (SUM149, HCC70 
and HCC1143). 
E. Xenografts of LAR MDA-MB-453 cells, treated daily with vehicle (n=10) or palbociclib 
(n=10) for 2 weeks. p<0.0001 Student’s T test vehicle vs. palbociclib at end of treatment..  
 
Figure 2: Palbociclib-sensitive cell lines have low post-mitotic CDK2 activity 
A. Left: Schematic of CDK2 activity live-cell sensor (CDK2L-GFP). CDK2 consensus 
phosphorylation sites shown: S=serine and T=threonine. NLS=nuclear localization signal. 
NES= nuclear export signal. Left. Phosphorylation of CDK2L-GFP sensor by active CDK2 
leads to export from the nucleus to the cytoplasm. Right. Schematic of changes in sensor 
localisation through the cell cycle. CDK2 activity is at its highest during S/G2 phase of the 
cell cycle. Fluorescence images correspond to CDKL2-GFP in a single MFM223 cell. 
B. and C. Single cell CDK2 activity traces of B. palbociclib-sensitive LAR MFM223, n=20 
cells, 20% CDK2high and C. palbocicilb-resistant basal-like SUM149, n=30 cells, 74% 
CDK2high. 
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D. Post-mitotic (2 hours post-cytokinesis) CDK2 activity in individual cells from five TNBC 
cell lines. LAR MFM223 vs. basal-like SUM149 cell lines (Student’s T-test p<0.0001). LAR 
MDAMB453 vs. basal-like SUM149 (p<0.0002). LAR=luminal androgen receptor subgroup 
(light blue), MES=mesenchymal (grey) and BASAL=basal-like (dark blue). 
E. Cell cycle lengths (hours) in post-mitotic CDK2high vs. CDK2low subpopulations in CAL51 
(p<0.0001 Student’s T test).  
 
Figure 3: The proliferative CDK2high subpopulation drives resistance to CDK4/6 
Inhibition at the single cell level 
A. Cells with low CDK2 activity post-mitosis do not re-enter the cell cycle when exposed to 
palbociclib. Heat-map of CDK2 activity in individual SUM149 cells treated with vehicle (left; 
n=37) or palbociclib (right; n=32) added 1-3 hours post-cytokinesis. CDK2 activity was 
synchronized and aligned in silico to point of cytokinesis (mitosis, M, yellow). T=0 hours 
corresponds to CDK2 activity post-cytokinesis and prior to palbociclib/vehicle addition. Each 
row represents one single cell. Heat map is ordered by CDK2 activity post-mitosis.  
B. Quantification of cells undergoing a second mitosis in SUM149 cells exposed to 
palbociclib 1-3 hours post-mitosis as in part A, post-mitosis CDK2 activity CDK2high versus 
CDK2low. Cells that underwent a second mitosis (yellow) versus those that did not underwent 
a second mitosis (blue) during the tracking period (p=0.0001 Fisher’s exact test). 
C. Relative BrdU incorporation in MFM223 and MFM223pR treated with vehicle, palbociclib 
500nmol and 1000nmol for 72 hours (Student’s T-test p<0.002 and p<0.004).  
D. Western blot of MFM223 and MFM223pR cells treated with vehicle or palbociclib 500nmol 
for 72 hours and probed with the indicated antibodies. 
E. Single cell CDK2 activity traces of cells grown in 500nmol Palbociclib Left: parental 
MFM223, Right: Palbocicilb-resistant MFM223pR. Red: Cells with CDK2 activity>1 at 10 
hours (proliferating). Black: Cells with CDK2 activity <1 at 10 hours (quiescent). 
 
Figure 4: High cyclin E1 expression post-mitosis drives high CDK2 activity and 
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CDK4/6 inhibitor resistance. 
A. Western blot of lysates from a panel of TNBC cell lines (n=11 cell lines), probed with the 
indicated antibodies (Not shown: Densitometry for LAR vs. non-LAR for androgen receptor 
(AR) p=0.01; Cyclin E1 p= 0.02; Mann-Whitney test).  
B. Copy number aberrations (CNA upper track) and gene expression (mRNA lower track) 
from 219 primary triple negative breast cancers, clustered according to gene expression 
subtypes: LAR (n=35); MSL (n=38); MES (n=49); Basal-like (n=97). P values generated from 
multiple t-tests (1% false discovery rate) for gene expression comparisons LAR vs. basal-like 
TNBC subtypes: Cyclin E1 (CCNE1) p<0.0001; CDK2 p<0.0001; CDKN1A (p21) p=0.06; 
CDKN1B (p27) p=0.23. Copy number gain LAR vs. basal-like: CCNE1 p=0.0082. Red: 
statistical significance. 
C. Immunofluorescent staining of nuclear cyclin E1 (red) in CDK2L positive (GFP) MDA-MB-
453 cells and SUM149 cells 1 hour after mitosis. DAPI (blue). 
D. Cyclin E1 nuclear intensity assessed by immunofluorescence and quantified with 
Columbus software in individual cells 1-2 hours post-mitosis, in LAR MDAMB453 and Basal-
like SUM149 cell lines (p= 0.094 Student’s T-test).  
E. Cyclin E1 nuclear intensity assessed by immunofluorescence in SUM149 cells 1-2 hours 
post-cytokinesis in CDK2low versus CDK2high cells (p value <0.0001 Student’s T-test).  
F. Single cell CDK2 activity traces of proliferating SUM149 cells transfected 72 hours earlier 
with siCON1 or siCCNE1. 
G. Relative BrdU incorporation in CAL51 cells transfected 72 hours earlier with siCON1, 
multiple individual CCNE1 siRNAs and siCCNE1 pool, treated with vehicle or palbociclib 
500nmol. H. Relative BrdU incorporation in MFM223 and MFM223pR cells transfected with 
the indicated siRNAs and treated with vehicle or palbociclib.  
 
Figure 5: Post-mitotic CDK2 activity is determined pre-mitosis  
A. Correlation of CDK2 activity 2 hours post-cytokinesis between the daughter cell pairs 
generated in the same mitosis, in CAL51 (left) and SUM149 (right).  
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B. Schematic illustrating shared levels of CDK2 activity between daughter cells. 
C. Time to S phase entry for SUM149 cells which divided between 0-2 hours after palbociclib 
was added. Pre-mitotic CDK activity (-2hrs) was measured in cells before palbociclib 
addition. Red: cells with pre-mitotic CDK2 activity >2; Grey: cells with pre-mitotic activity 
<2.0, none of which entered S phase by time-point 50 hours, post cytokinesis (p=0.016 
Mann-Whitney). 
D. SUM149 cells were single cell sorted by FACS and clones expanded from single cells for 
4 weeks before transfection with CDK2L-GFP sensor (left). Percentage of CDK2low and 
CDK2high SUM149 cells per well, 50 cells tracked per well (right).  
E. Percentage of cell positive for gamma H2AX (E3=total 860 cells; F7 =total 1508), 53BP1 
(E3=total 719 cells; F7 =total 1298) and p21 (E3=total 275 cells; F7 =total 539) by 
immunofluorescence in the predominately CDK2low E3 clones and CDK2high F7 clone.  
F. Immunofluorescence staining of p21 (yellow) in SUM149 cells transfected with CDK2 
biosensor (green) 
G. CDK2 activity in SUM149 cell in relation to the p21 staining status at 6 hours post-mitosis 
in SUM149 cells. Left: CDK2 activity traces and Right: CDK2 activity at 2 hours post 
cytokinesis, in p21 positive and p21 negative cells. 
 
Figure 6: Inhibition of PI3 kinase signalling synergises with CDK4/6 inhibition in 
PIK3CA mutant TNBC. 
A. Synergy heat maps matrices of clonogenic assays in TNBC cell lines treated with 
palbociclib and/or pictilisib (PI3 Kinase inhibitor) at increasing concentrations. Red: cell lines 
with combination synergy assessed using Bliss additivity score. PIK3CA mut = PIK3CA 
mutant. The lowest Bliss additivity score for each cell line is indicated. 
B. Clonogenic assays in PIK3CA mutant SUM159 MSL TNBC cell line grown in palbociclib 
500nmol, pictilisib (pan-PI3 kinase inhibitor) 200nmol, taselisib (alpha specific PI3 kinase 
inhibitor) 100nmol, and indicated combinations. 
C. Mouse xenografts of LAR MDAMB453 cells, treated daily with vehicle (n=10), palbociclib 
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(n=10), taselisib (n=10) or combination (n=10) (p=0.02 palbociclib vs. combination p=0.02; 
taselisib vs. combination p=0.01). Error bars are mean tumour volume and SD. 
D. Left: Immunohistochemistry of MDAMB453 mouse xenografts stained for phosphorylated 
RB1 (Ser807/811) after 1 and 4 hours of indicated drug treatment(s). Right: Scatter plots 
with percentage of positively stained cells for phosphorylated RB1 in IHC sections (left) after 
1 hour and 4 hours treatment.  
E. CDK2 activity post-mitosis in PIK3CA mutant CAL51 treated with vehicle or taselisib 
100nmol.  
F. Model of cell cycle dynamics in CDK2low cells. Cells exits mitosis into a quiescent state 
with CDK4/6 activity (blue) necessary to pass through the restriction point (yellow circle) 
after which CDK2 activity (red) promotes S phase entry.  
G. Model of cell cycle dynamics in CDK2high cells. Cells exit mitosis into an active 
proliferating state with high CDK2 activity, bypassing the restriction point, and CDK4/6 
activity is not necessary to enter S phase. Consequently CDK2high cells, and cancers with a 
high proportion of CDK2high cells, are resistant to CDK4/6 inhibition. 
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Fig. 1 LAR subgroup of TNBC is sensitive to CDK4/6 inhibition 
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Fig. 2 Palbociclib-sensitive cell lines have low postmitotic CDK2 activity. 
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Figure 3. The proliferative CDK2high subpopulation drives resistance to CDK4/6 inhibition at the 
single-cell level. 
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Figure 4. High cyclin E1 expression after mitosis drives high CDK2 activity and CDK4/6 inhibitor 
resistance 
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Figure 5. Postmitotic CDK2 activity is determined before mitosis. 
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Figure 6. Inhibition of PI3K signaling synergizeswith CDK4/6 inhibition in PIK3CA-mutant TNBC. 
 
